Led by $880.85m asset transaction with Novasep Holding, Europe’s medical devices industry saw a drop of 8.95% in deal activity during Q1 2021, when compared to the last four-quarter average, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
A total of 89 deals worth $2.99bn were announced for the region during Q1 2021, against the last four-quarter average of 97.75 deals.
Of all the deal types, venture financing saw most activity in Q1 2021 with 46 deals, representing a 51.7% share for the region.
In second place was M&A with 36 deals, followed by private equity deals with seven transactions, respectively capturing a 40.5% and 7.9% share of the overall deal activity for the quarter.
In terms of value of deals, M&A was the leading category in Europe’s medical devices industry with $2.38bn, while venture financing and private equity deals totalled $391.2m and $228m, respectively.
Europe medical devices industry deals in Q1 2021: Top deals
The top five medical devices deals accounted for a 71.8% share of the overall value during Q1 2021.
The combined value of the top five deals stood at $2.15bn, against the overall value of $2.99bn recorded for the quarter.
The top five medical devices industry deals of Q1 2021 tracked by GlobalData were:
1) Thermo Fisher Scientific’s $880.85m asset transaction with Novasep Holding
2) The $591m acquisition of Oxford Immunotec by PerkinElmer
3) Savaria’s $409.7m acquisition of Handicare Group
4) The $159m acquisition deal with Diagenode by Hologic
5) Sino Biopharmaceutical’s venture financing with Softhale for $110m.
Related Companies
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.